Lexicon Pharmaceuticals (NASDAQ:LXRX) has been given a consensus recommendation of “Hold” by the nine brokerages that are presently covering the stock, Marketbeat.com reports. Two investment analysts have rated the stock with a sell rating, four have assigned a hold rating and three have given a buy rating to the company. The average 1-year price target among analysts that have issued a report on the stock in the last year is $25.25.
LXRX has been the subject of a number of analyst reports. Wedbush lifted their target price on shares of Lexicon Pharmaceuticals from $38.00 to $40.00 and gave the stock an “outperform” rating in a report on Monday, April 16th. BidaskClub lowered shares of Lexicon Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Monday, February 5th. JPMorgan Chase lowered shares of Lexicon Pharmaceuticals from a “neutral” rating to an “underweight” rating and lowered their target price for the stock from $15.00 to $10.00 in a report on Wednesday, February 14th. Zacks Investment Research raised shares of Lexicon Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, February 13th. Finally, ValuEngine cut shares of Lexicon Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Friday, February 2nd.
LXRX traded down $0.01 during trading on Friday, reaching $9.80. 5,060 shares of the company’s stock were exchanged, compared to its average volume of 607,548. The company has a debt-to-equity ratio of 8.85, a quick ratio of 2.70 and a current ratio of 2.72. Lexicon Pharmaceuticals has a fifty-two week low of $9.74 and a fifty-two week high of $9.93. The firm has a market capitalization of $1.05 billion, a PE ratio of -7.72 and a beta of 0.42.
Lexicon Pharmaceuticals (NASDAQ:LXRX) last released its earnings results on Thursday, May 3rd. The biopharmaceutical company reported ($0.40) EPS for the quarter, topping analysts’ consensus estimates of ($0.43) by $0.03. Lexicon Pharmaceuticals had a negative net margin of 140.09% and a negative return on equity of 213.31%. The firm had revenue of $25.21 million during the quarter, compared to analyst estimates of $25.30 million. During the same quarter in the previous year, the business earned ($0.33) EPS. The business’s quarterly revenue was up 37.8% compared to the same quarter last year. equities analysts forecast that Lexicon Pharmaceuticals will post -1.33 EPS for the current year.
Several hedge funds and other institutional investors have recently made changes to their positions in LXRX. Wells Fargo & Company MN boosted its position in shares of Lexicon Pharmaceuticals by 27.2% during the third quarter. Wells Fargo & Company MN now owns 112,721 shares of the biopharmaceutical company’s stock worth $1,385,000 after purchasing an additional 24,131 shares in the last quarter. Schwab Charles Investment Management Inc. boosted its position in shares of Lexicon Pharmaceuticals by 5.6% during the third quarter. Schwab Charles Investment Management Inc. now owns 204,129 shares of the biopharmaceutical company’s stock worth $2,509,000 after purchasing an additional 10,811 shares in the last quarter. Cubist Systematic Strategies LLC bought a new position in shares of Lexicon Pharmaceuticals during the third quarter worth $149,000. Malaga Cove Capital LLC boosted its position in shares of Lexicon Pharmaceuticals by 37.5% during the fourth quarter. Malaga Cove Capital LLC now owns 59,387 shares of the biopharmaceutical company’s stock worth $587,000 after purchasing an additional 16,198 shares in the last quarter. Finally, Quantitative Systematic Strategies LLC bought a new position in shares of Lexicon Pharmaceuticals during the fourth quarter worth $117,000.
Lexicon Pharmaceuticals Company Profile
Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products for the treatment of human diseases. The company offers XERMELO, an orally-delivered small molecule drug candidate for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog therapy in adults.
Receive News & Ratings for Lexicon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexicon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.